Ascendis Pharma A/S
ASND
58 hedge funds and large institutions have $1.04B invested in Ascendis Pharma A/S in 2017 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 2 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 2
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
71% more funds holding
Funds holding: 34 → 58 (+24)
61% more capital invested
Capital invested by funds: $646M → $1.04B (+$397M)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
16.71% more ownership
Funds ownership: 71.6% → 88.3% (+17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$18.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$17.1M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.2M |
| 5 |
DM
Deerfield Management
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$15.4M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$12.2M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.29M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$922K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$12.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Tudor Investment Corp
Stamford,
Connecticut
| $215K | +$170K | +5,918 | New |
|
52
Victory Capital Management
San Antonio,
Texas
| $194K | +$154K | +5,358 | New |
|
53
Barclays
London,
United Kingdom
| $181K | +$143K | +5,000 | New |
|
54
Bank of America
Charlotte,
North Carolina
| $160K | -$11.2K | -392 | -8% |
|
|
55
Bank of Montreal
Toronto,
Ontario, Canada
| $149K | -$12.5K | -437 | -10% |
|
56
UBS Group
Zurich,
Switzerland
| $19K | +$14.8K | +515 | New |
|
|
LTFS
57
Ladenburg Thalmann Financial Services
Miami,
Florida
| $4K | +$2.87K | +100 | New |
|
58
US Bancorp
Minneapolis,
Minnesota
| $3K | – | – | – |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| $2K | +$1.64K | +57 | New |
|
|
60
Janus Henderson Group
London,
United Kingdom
| – | -$15.4M | -554,865 | Closed |
|
61
Creative Planning
Overland Park,
Kansas
| – | -$10K | -350 | Closed |
|
ASND Hedge Fund Activity: Q3 2017 in Review
58 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2017, worth a combined $1.04B — up 61% from $646M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ASND positions and 2 closed out — a net gain of 24 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $18.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $15.4M sold.
- 58 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2017, up from 34 in Q2 2017.
- Funds reported $1.04B of Ascendis Pharma A/S stock for Q3 2017, up 61% quarter-over-quarter.
- 26 funds opened new Ascendis Pharma A/S positions in Q3 2017 and 2 closed out, a net change of +24 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2017 was Avoro Capital Advisors, an estimated $18.5M added.
- The largest Ascendis Pharma A/S seller in Q3 2017 was Janus Henderson Group, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2017.